Teva will not market its generic version of FIRDAPSE in the U.S. any earlier than February 25, 2035, absent the occurrence of other conditions. The two remaining ANDA litigations regarding FIRDAPSE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback